kechowpharma
Kechow Pharma (Shanghai Kezhou Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Shanghai's Zhangjiang High-Tech Park. It focuses on innovative small-molecule drug research and development in oncology and free-radical-related diseases, pursuing Best-in-Class therapeutics based on independent intellectual property. Its lead approved product is Kelopin (tolametinib), a MEK inhibitor for advanced NRAS-mutant melanoma. Surfaced as a portfolio company of Qiming Venture Partners; no public developer or API surface was found during enrichment.
kechowpharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceutical, Biopharmaceutical, Oncology, and Drug Development.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API